Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19

Inclusion Criteria: * 1\. Individuals male or female ≥18 years of age at time of enrolment * 2.Subject (or legally authorized representative provides non opposition form prior to initiation of any study procedure. * 3\. Understands and agrees to comply with planned study procedure. (Agrees to the collection of venous blood per protocol). * 4\. Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen\<72hours prior to enrollment and/or a chest CT scan reported as highly likely SARS-CoV2 infection. The different scales for severity are as follows: * 5\. Non severe patients: Clinical assessment (evidence of rales/crackles on exam) or CT scan involvement AND SpO2\> 94% on room air, or ≤ 94% on room air but \> 94% with nasal Oxygen with a flow rate \<= 3l O2/min For the severe infection's patients' group: * 6\. Patients requiring mechanical ventilation and/or supplemental oxygen \>= 6l O2/min For the obese patients 'group: * 7\. Obese patients will be defined as an BMI \> 30 * 8\. Co inclusion in non-interventional researches is possible Exclusion Criteria: * Pregnant and breast-feeding women * Patients previously treated by phenelzine (Nardil®) * Persons unable to give their no opposition * Persons under guardianship or curatorship * No affiliated to social insurance. * Inclusion in interventional researches